Chemo-informatics Guided Study of Natural Inhibitors Targeting Rho GTPase: a Lead for Treatment of Glaucoma

Overview

Journal In Silico Pharmacol

Date 2021 Jan 14

PMID 33442531

Citations 3

Authors

Sumit Kumar Rai

Rajesh Kumar Pathak

Dev Bukhsh Singh

Arun Bhatt

Mamta Baunthiyal

Affiliations

Soon will be listed here.

Abstract

Glaucoma, the most perilous disease leading to blindness is a result of optical neuropathy. Accumulation of aqueous humor in the posterior chamber due to a large difference in the rate of formation and its drainage in the anterior chamber causes an increase in intraocular pressure (IOP) leading to damage of nerve cells. A literature survey has revealed that inhibition of the Rho guanosine triphosphatases (rho GTPase) pathway by specific inhibitors leads to the relaxation of contractile cells involved in the aqueous outflow pathway. Relaxation of the strained contractile cells results in increased outflow thereby releasing IOP. In the present study molecular docking has been used to screen twenty seven bioactive (17 natural compounds and 10 conventional drugs) compounds that may play a significant role in relaxing contractile cells by inhibiting rho-GTPase protein. Docking results showed that among all-natural bioactive compounds Cyanidin and Delphinidine have a good binding affinity (- 8.4 kcal/mol) than the top screened conventional drug molecule Mitomycin, (- 6.3 kcal/mol) when docked with rho-GTPase protein. Cyanidin and Delphinidin belong to anthocyanidin, a glycoside form of anthocyanins from L. and The resembling potential of Cyanidin and Delphinidin concerning the drug Mitomycin was confirmed through simulation analysis. Molecular dynamics study (MDS) for 100 ns, showed that the rho GTPase-Delphinidine complex structure was energetically more stable than rho GTPase-Cyaniding complex in comparison to rho GTPase-Mitomycin complex. The comparative study of both the selected hits (Cyanidin and Delphinidin) was assessed by RMSD, RMSF, Rg, SASA, H-bond, PCA MM/PBSA analysis. The analysis revealed that Delphinidine is more potent to inhibit the rho GTPase as compare to Cyaniding and available conventional drugs in terms of stability and binding free energy. Based on the results, these molecules have good pharmacokinetic and pharmacodynamics properties and will prove to be a promising lead compound as a future drug for Glaucoma.

Citing Articles

The discovery of subunit-selective GluN1/GluN2B NMDAR antagonist via pharmacophere-based virtual screening.

Tang J, Jin J, Huang Z, An F, Huang C, Jiang W Exp Biol Med (Maywood). 2024; 248(24):2560-2577.

PMID: 38282535 PMC: 10854469. DOI: 10.1177/15353702231220666.

Unraveling structural and conformational dynamics of DGAT1 missense nsSNPs in dairy cattle.

Pathak R, Lim B, Park Y, Kim J Sci Rep. 2022; 12(1):4873.

PMID: 35318385 PMC: 8940929. DOI: 10.1038/s41598-022-08833-6.

Structural insights into inhibition of PRRSV Nsp4 revealed by structure-based virtual screening, molecular dynamics, and MM-PBSA studies.

Pathak R, Seo Y, Kim J J Biol Eng. 2022; 16(1):4.

PMID: 35193698 PMC: 8864930. DOI: 10.1186/s13036-022-00284-x.

References

Pathak R, Baunthiyal M, Taj G, Kumar A . Virtual screening of natural inhibitors to the predicted HBx protein structure of Hepatitis B Virus using molecular docking for identification of potential lead molecules for liver cancer. Bioinformation. 2014; 10(7):428-35. PMC: 4135291. DOI: 10.6026/97320630010428. View

Shukla R, Shukla H, Tripathi T . Activity loss by H46A mutation in Mycobacterium tuberculosis isocitrate lyase is due to decrease in structural plasticity and collective motions of the active site. Tuberculosis (Edinb). 2018; 108:143-150. DOI: 10.1016/j.tube.2017.11.013. View

Quigley H, Addicks E, Green W, MAUMENEE A . Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol. 1981; 99(4):635-49. DOI: 10.1001/archopht.1981.03930010635009. View

Higginbotham E, Gordon M, Beiser J, Drake M, Bennett G, Wilson M . The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol. 2004; 122(6):813-20. DOI: 10.1001/archopht.122.6.813. View

Burgoyne C, Crawford Downs J, Bellezza A, Suh J, Hart R . The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog Retin Eye Res. 2004; 24(1):39-73. DOI: 10.1016/j.preteyeres.2004.06.001. View

Ziarek J, Peterson F, Lytle B, Volkman B . Binding site identification and structure determination of protein-ligand complexes by NMR a semiautomated approach. Methods Enzymol. 2011; 493:241-75. PMC: 3635485. DOI: 10.1016/B978-0-12-381274-2.00010-8. View

Kass M, Gordon M, Kymes S . Incorporating the results of the Ocular Hypertension Treatment Study into clinical practice. Arch Ophthalmol. 2005; 123(7):1021-2. DOI: 10.1001/archopht.123.7.1021-b. View

Mamgain S, Sharma P, Pathak R, Baunthiyal M . Computer aided screening of natural compounds targeting the E6 protein of HPV using molecular docking. Bioinformation. 2015; 11(5):236-42. PMC: 4464539. DOI: 10.6026/97320630011236. View

Hollands H, Johnson D, Hollands S, Simel D, Jinapriya D, Sharma S . Do findings on routine examination identify patients at risk for primary open-angle glaucoma? The rational clinical examination systematic review. JAMA. 2013; 309(19):2035-42. DOI: 10.1001/jama.2013.5099. View

10.

Thumkeo D, Shimizu Y, Sakamoto S, Yamada S, Narumiya S . ROCK-I and ROCK-II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo. Genes Cells. 2005; 10(8):825-34. DOI: 10.1111/j.1365-2443.2005.00882.x. View

11.

Shurin G, Tourkova I, Shurin M . Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells. J Immunother. 2008; 31(5):491-9. PMC: 4001709. DOI: 10.1097/CJI.0b013e318176fae4. View

12.

Kwon Y, Fingert J, Kuehn M, Alward W . Primary open-angle glaucoma. N Engl J Med. 2009; 360(11):1113-24. PMC: 3700399. DOI: 10.1056/NEJMra0804630. View

13.

Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y . Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003; 9(7):2632-41. View

14.

Roche D, Brackenridge D, McGuffin L . Proteins and Their Interacting Partners: An Introduction to Protein-Ligand Binding Site Prediction Methods. Int J Mol Sci. 2015; 16(12):29829-42. PMC: 4691145. DOI: 10.3390/ijms161226202. View

15.

Somlyo A, Somlyo A . Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev. 2003; 83(4):1325-58. DOI: 10.1152/physrev.00023.2003. View

16.

Mardilovich K, Olson M, Baugh M . Targeting Rho GTPase signaling for cancer therapy. Future Oncol. 2012; 8(2):165-77. DOI: 10.2217/fon.11.143. View

17.

Kolluru G, Majumder S, Chatterjee S . Rho-kinase as a therapeutic target in vascular diseases: striking nitric oxide signaling. Nitric Oxide. 2014; 43:45-54. DOI: 10.1016/j.niox.2014.09.002. View

18.

Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

19.

Julian L, Olson M . Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases. 2014; 5:e29846. PMC: 4114931. DOI: 10.4161/sgtp.29846. View

20.

Meiers S, Kemeny M, Weyand U, Gastpar R, von Angerer E, Marko D . The anthocyanidins cyanidin and delphinidin are potent inhibitors of the epidermal growth-factor receptor. J Agric Food Chem. 2001; 49(2):958-62. DOI: 10.1021/jf0009100. View